Iradimed (IRMD) Net Margin (2013 - 2026)

Iradimed (IRMD) has 14 years of Net Margin data on file, last reported at 26.47% in Q1 2026.

• On a quarterly basis, Net Margin rose 245.0% year-over-year to 26.47% in Q1 2026; TTM through Mar 2026 was 27.28%, a 188.0% increase from a year earlier, with the FY2025 full-year figure at 26.73%, up 142.0% from the prior year.
• Net Margin for Q1 2026 stood at 26.47%, down from 28.06% in the prior quarter.
• Over the last five years, Net Margin for IRMD reached as high as 30.7% in Q3 2023 and fell as low as 17.86% in Q4 2023.
• Historically, Net Margin has averaged 25.14% across 5 years, with a median of 25.56% in 2022.
• On a YoY basis, Net Margin climbed as much as 1050 bps in 2022 and fell as far as 1180 bps in 2022.
• Year by year, Net Margin stood at 25.15% in 2022, then declined by 29 bps to 17.86% in 2023, then grew by 28 bps to 22.94% in 2024, then grew by 22 bps to 28.06% in 2025, then declined by 6 bps to 26.47% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 26.47% in Q1 2026, 28.06% in Q4 2025, and 26.3% in Q3 2025.